Abstract

Therapeutic drug monitoring (TDM) of biologics - encompassing the measurement of (trough) concentrations and anti-drug antibodies - is emerging as a valuable tool for clinical decision-making. While this strategy needs further validation, attention for its implementation into the clinic is warranted. Rapid testing and easy sampling are key to its implementation. Here, we aimed to evaluate the feasibility and volunteers’ perception of home microsampling for quantification of adalimumab (ADM) concentrations in psoriasis patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call